RT Journal Article
T1 Role of microRNAs in the Development of Cardiovascular Disease in Systemic Autoimmune Disorders
A1 Lopez-Pedrera, Chary
A1 Barbarroja, Nuria
A1 Patiño-Trives, Alejandra Mª
A1 Luque-Tévar, Maria
A1 Torres-Granados, Carmen
A1 Aguirre-Zamorano, Mª Angeles
A1 Collantes-Estevez, Eduardo
A1 Pérez-Sánchez, Carlos
K1 Systemic autoimmune diseases
K1 Antiphospholipid syndrome
K1 Systemic lupus erythematosus
K1 Rheumatoid arthritis
K1 Atherosclerosis
K1 Thrombosis
K1 Cardiovascular diasease
K1 MicroRNAs
K1 Síndrome antifosfolípido
K1 Lupus eritematoso sistémico
K1 Artritis reumatoide
K1 Aterosclerosis
K1 Trombosis
K1 Enfermedades cardiovasculares
K1 MicroARNs
AB Rheumatoid Arthritis (RA), Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are the systemic autoimmune diseases (SADs) most associated with an increased risk of developing cardiovascular (CV) events. Cardiovascular disease (CVD) in SADs results from a complex interaction between traditional CV-risk factors, immune deregulation and disease activity. Oxidative stress, dyslipidemia, endothelial dysfunction, inflammatory/prothrombotic mediators (cytokines/chemokines, adipokines, proteases, adhesion-receptors, NETosis-derived-products, and intracellular-signaling molecules) have been implicated in these vascular pathologies. Genetic and genomic analyses further allowed the identification of signatures explaining the pro-atherothrombotic profiles in RA, SLE and APS. However, gene modulation has left significant gaps in our understanding of CV co-morbidities in SADs. MicroRNAs (miRNAs) are emerging as key post-transcriptional regulators of a suite of signaling pathways and pathophysiological effects. Abnormalities in high number of miRNA and their associated functions have been described in several SADs, suggesting their involvement in the development of atherosclerosis and thrombosis in the setting of RA, SLE and APS. This review focusses on recent insights into the potential role of miRNAs both, as clinical biomarkers of atherosclerosis and thrombosis in SADs, and as therapeutic targets in the regulation of the most influential processes that govern those disorders, highlighting the potential diagnostic and therapeutic properties of miRNAs in the management of CVD.
PB MDPI
YR 2020
FD 2020-03-16
LK http://hdl.handle.net/10668/3607
UL http://hdl.handle.net/10668/3607
LA en
NO Lopez-Pedrera C, Barbarroja N, Patiño-Trives AM, Luque-Tévar M, Torres-Granados C, Aguirre-Zamorano MA, et al. Role of microRNAs in the Development of Cardiovascular Disease in Systemic Autoimmune Disorders. Int J Mol Sci. 2020 Mar 16;21(6):2012
DS RISalud
RD Apr 10, 2025